Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF
- PMID: 7890302
- PMCID: PMC1415193
Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF
Abstract
Soluble tumour necrosis factor receptors (sTNF-R) are up-regulated at sites of chronic inflammation such as rheumatoid synovial joints. The p75 sTNF-R is the more abundant, suggesting an important role for this TNF inhibitor in regulating TNF bioactivity in vivo. As the precise cellular source of these soluble receptors is not known, we investigated the production and regulation of sTNF-R by T lymphocytes, an abundant cell type in inflammatory infiltrates, which upon activation express high levels of p75 surface receptors. Using panels of T-cell lines and clones expressing high levels of p75 TNF-R, we found that p75 sTNF-R production upon stimulation is a feature common to all subsets of T cells, including cells of the CD4-CD8- double negative phenotype expressing either alpha beta or gamma delta T-cell receptors (TCR). In contrast, levels of p55 sTNF-R were only detected when T cells were stimulated at higher densities and by potent mitogens such as phorbol 12-myristate 13-acetate (PMA). Detailed kinetic analyses revealed that the production of p75 sTNF-R was biphasic, the first phase was activation dependent, occurring in the absence of detectable TNF, while the second phase of p75 sTNF-R production was regulated by cytokines such as TNF. Unlike short-term exposure to TNF which enhances sTNF-R production in vitro and in vivo, prolonged exposure of T lymphocytes to TNF suppressed p75 sTNF-R (but not p55 sTNF-R) production in a dose- and time-dependent fashion. These results suggest that in patients with chronic inflammatory disease, which are exposed to augmented levels of bioactive TNF for prolonged periods, the production of p75 sTNF-R may be impaired.
Similar articles
-
The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.Eur Cytokine Netw. 1998 Jun;9(2):145-54. Eur Cytokine Netw. 1998. PMID: 9681390 Clinical Trial.
-
Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection.J Interferon Cytokine Res. 1995 Sep;15(9):749-57. doi: 10.1089/jir.1995.15.749. J Interferon Cytokine Res. 1995. PMID: 8536102
-
Tumor necrosis factor alpha and interleukin-1 alpha stimulate late shedding of p75 TNF receptors but not p55 TNF receptors from human monocytes.J Interferon Cytokine Res. 1995 Nov;15(11):947-54. doi: 10.1089/jir.1995.15.947. J Interferon Cytokine Res. 1995. PMID: 8590306
-
[Soluble TNF p55 and p75 receptors in the development of sepsis syndrome].Pol Merkur Lekarski. 2003 Jan;14(79):69-72. Pol Merkur Lekarski. 2003. PMID: 12712835 Review. Polish.
-
PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I73-81. doi: 10.1136/ard.58.2008.i73. Ann Rheum Dis. 1999. PMID: 10577978 Free PMC article. Review.
Cited by
-
Differential expression, shedding, cytokine regulation and function of TNFR1 and TNFR2 in human fetal astrocytes.Yonsei Med J. 2005 Dec 31;46(6):818-26. doi: 10.3349/ymj.2005.46.6.818. Yonsei Med J. 2005. PMID: 16385659 Free PMC article.
-
Soluble tumour necrosis factor (TNF)-receptor levels in serum as markers of anti-viral host reactivity.Clin Exp Immunol. 1999 May;116(2):299-306. doi: 10.1046/j.1365-2249.1999.00903.x. Clin Exp Immunol. 1999. PMID: 10337022 Free PMC article.
-
Shedding of TNF receptor 2 by effector CD8⁺ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection.J Leukoc Biol. 2015 Sep;98(3):423-34. doi: 10.1189/jlb.3A0914-432RR. Epub 2015 May 27. J Leukoc Biol. 2015. PMID: 26019295 Free PMC article. Clinical Trial.
-
Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis.Ann Rheum Dis. 1996 Apr;55(4):243-7. doi: 10.1136/ard.55.4.243. Ann Rheum Dis. 1996. PMID: 8733441 Free PMC article.
-
O-glycosylation and its role in therapeutic proteins.Biosci Rep. 2022 Oct 28;42(10):BSR20220094. doi: 10.1042/BSR20220094. Biosci Rep. 2022. PMID: 36214107 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials